Tamoxifen prevention of breast cancer: an instance of the fingerpost.

No abstract is available for this paper.

• Publication year

  1999

• Venue

  Journal of the National Cancer Institute

• Publication date

  1999-11-03

• Fields of study

  Medicine

• Identifiers
  DOI 10.1093/JNCI/91.21.1809PMID 10547388
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Journal of the National Cancer Institute, Vol. 29, 1962: Action of bacterial polysaccharide on tumors. II. Damage of sarcoma 37 by serum of mice treated with Serratia marcescens polysaccharide, and induced tolerance.

  2009cited by this paper
• Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-year Randomized Clinical Trial

  2000cited by this paper
• The Effect of Raloxifene on Risk of Breast Cancer in Postmenopausal Women: Results From the MORE Randomized Trial

  2000cited by this paper
• Tamoxifen hits the target in situ.

  1999cited by this paper
• Re: Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study.

  1999cited by this paper
• Putting the risk of breast cancer in perspective.

  1999cited by this paper
• MORE ABOUT : MULTIFACTORIAL ANALYSIS OF DIFFERENCES BETWEEN SPORADIC BREAST CANCERS AND CANCERS INVOLVING BRCA1 AND BRCA2 MUTATIONS. AUTHORS' REPLY

  1999cited by this paper
• Prophylactic mastectomy--the price of fear.

  1999cited by this paper
• cJun overexpression in MCF-7 breast cancer cells produces a tumorigenic, invasive and hormone resistant phenotype

  1999cited by this paper
• Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Efficacy of bilateral prophylactic mastectomy in women with a family history of breast cancer.

  1999cited by this paper
• Estrogen Receptor β Activates the Human Retinoic Acid Receptorα -1 Promoter in Response to Tamoxifen and Other Estrogen Receptor Antagonists, but Not in Response to Estrogen

  1999cited by this paper
• Tamoxifen, raloxifene, and the prevention of breast cancer.

  1999cited by this paper
• More about: multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.

  1999cited by this paper
• Randomized trial of fenretinide to prevent second breast malignancy in women with early breast cancer.

  1999cited by this paper
• Weighing the risks and benefits of tamoxifen treatment for preventing breast cancer.

  1999cited by this paper
• Mediation of N-(4-hydoxyphenyl)retinamide-induced apoptosis in human cancer cells by different mechanisms.

  1999cited by this paper
• Tamoxifen for prevention of breast cancer.

  1999cited by this paper
• Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study.

  1999cited by this paper
• Hemophagocytic syndrome in five patients with Epstein–Barr virus negative B‐cell lymphoma

  1999cited by this paper
• Ligand-activated retinoic acid receptor inhibits AP-1 transactivation by disrupting c-Jun/c-Fos dimerization.

  1999cited by this paper
• Retinoid receptor-dependent and -independent effects of N-(4-hydroxyphenyl)retinamide in F9 embryonal carcinoma cells.

  1999cited by this paper
• 4HPR triggers apoptosis but not differentiation in retinoid sensitive and resistant human embryonal carcinoma cells through an RARγ independent pathway

  1999cited by this paper
• Anhydroretinol induces oxidative stress and cell death.

  1999cited by this paper
• Transcriptional targets shared by estrogen receptor- related receptors (ERRs) and estrogen receptor (ER) alpha, but not by ERbeta.

  1999cited by this paper
• Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial.

  1999cited by this paper
• Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol.

  1999cited by this paper
• Effect of blood tamoxifen concentrations on surrogate biomarkers in a trial of dose reduction in healthy women.

  1999cited by this paper
• American Society of Clinical Oncology technology assessment on breast cancer risk reduction strategies: tamoxifen and raloxifene.

  1999cited by this paper
• Re: Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.

  1999cited by this paper
• Re: Variation in mammographic breast density by time in menstrual cycle among women aged 40-49 years.

  1999cited by this paper
• 5,6-trans-16-ene-vitamin D3: a new class of potent inhibitors of proliferation of prostate, breast, and myeloid leukemic cells.

  1999cited by this paper
• 6-trans-16-ene-Vitamin D 3 : A New Class of Potent Inhibitors of Proliferation of Prostate , Breast , and Myeloid Leukemic Cells 1

  1999cited by this paper
• Expression of estrogen receptor beta1, beta2, and beta5 messenger RNAs in human breast tissue.

  1999cited by this paper
• Retinoid signaling and activator protein-1 expression in ferrets given beta-carotene supplements and exposed to tobacco smoke.

  1999cited by this paper
• Co-carcinogenic effect of beta-carotene.

  1999cited by this paper
• Co-carcinogenic effect of β-carotene

  1999cited by this paper
• Novel indications for BRCA1 screening using individual clinical and morphological features

  1999cited by this paper
• The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation.

  1999cited by this paper
• National Surgical Adjuvant Breast and Bowel Project breast cancer prevention trial: a reflective commentary.

  1999cited by this paper
• Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers.

  1999cited by this paper
• Central hypothyroidism associated with retinoid X receptor-selective ligands.

  1999cited by this paper
• Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators.

  1999cited by this paper
• Receptor Antiestrogen EM-800 ( SC 5705 ) with the Human Estrogen The Interaction of Raloxifene and the Active Metabolite of the Updated Version

  1999cited by this paper
• Ductal carcinoma in situ--the focus for prevention, screening, and breast conservation in breast cancer.

  1999cited by this paper
• Relationship of arachidonic acid metabolizing enzyme expression in epithelial cancer cell lines to the growth effect of selective biochemical inhibitors.

  1999cited by this paper
• Regulation of hormone-induced histone hyperacetylation and gene activation via acetylation of an acetylase.

  1999cited by this paper
• Transcriptional targets shared by estrogen receptor‐related receptors (ERRs) and estrogen receptor (ER) α, but not by ERβ

  1999cited by this paper
• Distinct molecular pathogeneses of early-onset breast cancers in BRCA1 and BRCA2 mutation carriers: a population-based study.

  1999cited by this paper
• Estrogen receptor beta activates the human retinoic acid receptor alpha-1 promoter in response to tamoxifen and other estrogen receptor antagonists, but not in response to estrogen.

  1999cited by this paper
• Re: Cancer chemoprevention: progress and promise.

  1999cited by this paper
• Prevalence of BRCA1 and BRCA2 gene mutations in patients with early-onset breast cancer.

  1999cited by this paper
• Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance.

  1999cited by this paper
• Nuclear retinoid acid receptor beta in bronchial epithelium of smokers before and during chemoprevention.

  1999cited by this paper
• Validation studies for models projecting the risk of invasive and total breast cancer incidence.

  1999cited by this paper
• Re: Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.

  1999cited by this paper
• National Cancer Institute--supported cancer chemoprevention research: coming of age.

  1999cited by this paper
• BRCA1 inhibition of estrogen receptor signaling in transfected cells.

  1999cited by this paper
• Peptide antagonists of the human estrogen receptor.

  1999cited by this paper
• RRR‐α‐tocopheryl succinate induction of prolonged activation of c‐jun amino‐terminal kinase and c‐jun during induction of apoptosis in human MDA‐MB‐435 breast cancer cells

  1998cited by this paper
• Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group.

  1998cited by this paper
• Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma.

  1998cited by this paper
• Differences in breast cancer stage at diagnosis between non-Hispanic white and Hispanic populations, San Diego County 1988–1993

  1998cited by this paper
• Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study.

  1998cited by this paper
• Apoptosis induction and potent antiestrogen receptor-negative breast cancer activity in vivo by a retinoid antagonist.

  1998cited by this paper
• Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers.

  1998cited by this paper
• Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial.

  1998cited by this paper
• Variation in use of adjuvant tamoxifen

  1998cited by this paper
• Cancer chemoprevention: progress and promise.

  1998cited by this paper
• RRR-alpha-tocopheryl succinate induction of prolonged activation of c-jun amino-terminal kinase and c-jun during induction of apoptosis in human MDA-MB-435 breast cancer cells.

  1998cited by this paper
• Tamoxifen in the treatment of breast cancer.

  1998cited by this paper
• Tamoxifen in the Treatment of Breast Cancer

  1998cited by this paper
• Putting the risk of breast cancer in perspective

  1998cited by this paper
• Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations.

  1998cited by this paper
• Hormone status of in-situ cancer in BRCA1 and BRCA2 mutation carriers.

  1998cited by this paper
• Tamoxifen for Early Breast Cancer

  1998cited by this paper
• Effects of the antiestrogens tamoxifen, toremifene, and ICI 182,780 on endometrial cancer growth.

  1998cited by this paper
• Survival and tumour characteristics of breast-cancer patients with germline mutations of BRCA1.

  1998cited by this paper
• Breast cancer cells have lower activating protein 1 transcription factor activity than normal mammary epithelial cells.

  1997cited by this paper
• Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists

  1997cited by this paper
• Molecular basis of agonism and antagonism in the oestrogen receptor

  1997cited by this paper
• Induction of retinoid resistance in breast cancer cells by overexpression of cJun.

  1997cited by this paper
• Molecular determinants of tissue selectivity in estrogen receptor modulators.

  1997cited by this paper
• Tumour biological features of BRCA1-induced breast and ovarian cancer.

  1997cited by this paper
• Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites.

  1997cited by this paper
• Recent advances in chemoprevention of cancer.

  1997cited by this paper
• Expression of estrogen receptor-beta in human breast tumors.

  1997cited by this paper
• Retinoic acid treatment abrogates elastase-induced pulmonary emphysema in rats

  1997cited by this paper
• Bone mass and the risk of breast cancer among postmenopausal women.

  1997cited by this paper
• Progressive decrease in nuclear retinoic acid receptor beta messenger RNA level during breast carcinogenesis.

  1997cited by this paper
• Retinoid X receptor and peroxisome proliferator-activated receptor activate an estrogen responsive gene independent of the estrogen receptor.

  1997cited by this paper
• Methodologic Guidelines for Review Papers

  1997cited by this paper
• A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors.

  1996cited by this paper
• Chemoprevention of mammary carcinoma by LGD1069 (Targretin): an RXR-selective ligand.

  1996cited by this paper
• Potential role for retinoic acid receptor-gamma in the inhibition of breast cancer cells by selective retinoids and interferons.

  1996cited by this paper
• Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease.

  1996cited by this paper
• Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors.

  1996cited by this paper
• Activation and inhibition of the AP‐1 complex in human breast cancer cells

  1996cited by this paper
• Regulation of the human retinoic acid receptor alpha gene in the estrogen receptor negative human breast carcinoma cell lines SKBR-3 and MDA-MB-435.

  1996cited by this paper
• Lack of effect of long-term supplementation with beta carotene on the incidence of malignant neoplasms and cardiovascular disease.

  1996cited by this paper

• SIRT1–FOXO1 Signaling in Cancer

  2025cites this paper
• Analysis of the Main Directions in the Development of Mono and Combination Pharmacotherapy Acting on Hormonal Signaling Pathways of Breast Cancer According to the FDA Databases and Clinicaltrials.gov.

  2025cites this paper
• Tamoxifen protects photoreceptors in the sodium iodate model.

  2024cites this paper
• Chemoprevention—Historical Perspectives and Current Trends

  2024cites this paper
• Retrospective Analysis of the Effect of Postmenopausal Women Medications on SARS-CoV-2 Infection Progression

  2024cites this paper
• Mining TCGA Database for Genes with Prognostic Value in Breast Cancer

  2023cites this paper
• Breast Health

  2021cites this paper
• Raloxifene as a treatment option for viral infections

  2021cites this paper
• Assessment of common risk factors and validation of the Gail model for breast cancer: A hospital-based study from Western India

  2020cites this paper
• The Role of Breast Cancer Chemoprevention in High-Risk Women

  2018cites this paper
• Cancer and Chemoprevention: An Overview

  2017cites this paper
• Sodium Butyrate Attenuates Nephrotoxicity Induced by Tamoxifen in Rats.

  2016cites this paper
• Cancer Prevention: Obstacles, Challenges and the Road Ahead.

  2016cites this paper
• Development and application of a pathology supported pharmacogenetic test for improved clinical management of South African patients with breast cancer and associated co-morbidities

  2016cites this paper
• JNCI and cancer prevention.

  2015cites this paper
• Do Firms Underinvest in Long-Term Research? Evidence from Cancer Clinical Trials.

  2015cites this paper
• The challenges for cancer chemoprevention.

  2015cites this paper
• Do firms underinvest in long-term research ? Evidence from cancer clinical trials ∗

  2014cites this paper
• Skin Cancer Prevention

  2014cites this paper
• Toxicity and adverse effects of Tamoxifen and other anti-estrogen drugs.

  2013cites this paper
• Chemoprevention of Breast Cancer with Fenretinide

  2012cites this paper
• Skin Cancer Prevention

  2011cites this paper
• Predicting Adherence to Tamoxifen for Breast Cancer Adjuvant Therapy and Prevention

  2011cites this paper
• Baseline predictors of adherencea in studies of tamoxifen for prevention and / or adjuvant therapy of breast cancer

  2011cites this paper
• Breast Cancer Chemoprevention

  2010cites this paper
• Unprecedented Opportunities and Promise for Cancer Prevention Research

  2010cites this paper
• Computer Simulation Estimation of the Benefits and Costs of Breast Cancer Chemoprevention

  2009cites this paper
• The future of molecular-targeted cancer chemoprevention.

  2008cites this paper
• Cancer Survivors: A Physician’s Perspective

  2007cites this paper
• The Convergent Development of Molecular-Targeted Drugs for Cancer Treatment and Prevention

  2007cites this paper
• Chemoprevention of breast cancer: current status and future prospects.

  2006cites this paper
• Chemoprevention of breast cancer 2250 occurrence of breast cancer is correlated with estrogens , chemicals produced by the ovaries

  2006cites this paper
• Reducing the "risk" of chemoprevention: defining and targeting high risk--2005 AACR Cancer Research and Prevention Foundation Award Lecture.

  2006cites this paper
• How Should We Inform Women at Higher Risk of Breast Cancer About Tamoxifen? An Approach with a Decision Guide

  2005cites this paper
• Cancer prevention: strong science and real medicine.

  2005cites this paper
• Tamoxifen For Breast Cancer Chemoprevention: Low Uptake by High-Risk Women After Evaluation of a Breast Lump

  2005cites this paper
• TOBACCO CARCINOGEN-INDUCED 3~14.2 ALTERATIONS IN EXFOLIATED CELLS COLLECTED FROM THE ORAL CAVITY OF SMOKERS

  2005cites this paper
• Biological basis of cancer in the older person.

  2005cites this paper
• Prevention of hormone-related cancers: breast cancer.

  2005cites this paper
• Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction

  2005cites this paper
• The convergence of cancer prevention and therapy in early-phase clinical drug development.

  2004cites this paper
• Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.

  2004cites this paper
• Re: Effect of epidermal growth factor receptor inhibitor on development of estrogen receptor-negative mammary tumors.

  2004cites this paper
• Prevention of cancers of the breast, endometrium and ovary

  2004cites this paper
• Medikamentöse Prävention des Mammakarzinoms: eine Übersicht über die Literatur und den Stand in Deutschland

  2003cites this paper
• Non‐genomic effects of tamoxifen on the activation of membrane‐bound guanylate cyclase GC‐A

  2003cites this paper
• Frontiers in cancer prevention research.

  2003cites this paper
• Prevention of HER‐2/neu transgenic mammary carcinoma by tamoxifen plus interleukin 12

  2003cites this paper
• Characterization and chromosomal instability of novel derived cell lines from a wt-erbB-2 transgenic mouse model.

  2003cites this paper
• The prevention of breast cancer

  2003cites this paper
• Cancer prevention by delay. Commentary re: J. A. O'Shaughnessy et al., Treatment and Prevention of Intraepithelial Neoplasia: An Important Target for Accelerated New Agent Development. Clin. Cancer Res., 8: 314-346, 2002.

  2002cites this paper
• Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development.

  2002influential citation
• Cancer prevention clinical trials.

  2002cites this paper
• Progress in breast cancer chemoprevention.

  2002cites this paper
• Cancer prevention science and practice.

  2002cites this paper
• Cancer Prevention by Delay

  2002cites this paper
• Chemoprevention of Breast Cancer: A Summary of the Evidence for the U.S. Preventive Services Task Force

  2002cites this paper
• Endocrine-Related Cancer ( 2002 ) 9 15 – 32 Progress in breast cancer chemoprevention

  2002cites this paper
• Prevention in the balance.

  2002cites this paper
• [Is there progress in chemotherapy for breast cancer?].

  2001cites this paper
• Results and implications of the Royal Marsden and other tamoxifen chemoprevention trials: an alternative view.

  2001cites this paper
• First do no harm: extending the debate on the provision of preventive tamoxifen

  2001influential citation
• From Adjuvant Therapy to Breast Cancer Prevention: BCPT and STAR

  2001cites this paper
• Risk-reduction mastectomy: clinical issues and research needs.

  2001cites this paper
• Growth stimulatory angiotensin II type-1 receptor is upregulated in breast hyperplasia and in situ carcinoma but not in invasive carcinoma

  2001cites this paper
• Systemic therapy for older women with breast cancer.

  2001cites this paper
• [Medical management of women with inherited predisposition to breast cancer: indications and procedures for mammographic screening].

  2001cites this paper
• SERMs, Ethnicity, and Clinical Trials

  2001cites this paper
• Az emlôrák kemoprevenciója - különös tekintettel a tamoxifenre

  2001cites this paper
• Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer.

  2001cites this paper
• Lung cancer chemoprevention: an integrated approach.

  2001cites this paper
• Re: tamoxifen prevention of breast cancer: an instance of the fingerpost

  2000cites this paper
• Chemoprevention of breast cancer

  2000influential citation
• Cancer chemoprevention in the 21st century: genetics, risk modeling, and molecular targets.

  2000cites this paper
• Re: tamoxifen prevention of breast cancer: an instance of the fingerpost.

  2000cites this paper
• Advances in the development of retinoids as chemopreventive agents.

  2000cites this paper
• Protease inhibitors in oral carcinogenesis and chemoprevention.

  2000cites this paper
• The Biology Behind Protease Inhibitors in Oral Carcinogenesis and Chemoprevention

  2000cites this paper
• Epidemiology, prevention, and early detection of breast cancer

  2000cites this paper
• Primary cancer prevention trials.

  2000cites this paper
• Lung cancer chemoprevention.

  2000cites this paper
• RESPONSE: re: tamoxifen prevention of breast cancer: an instance of the fingerpost

  2000cites this paper
• Breast Cancer

  2000cites this paper
• Prevention with tamoxifen or other hormones versus prophylactic surgery in BRCA1/2-positive women: a decision analysis.

  2000cites this paper
• Re: tamoxifen prevention of breast cancer: an instance of the fingerpost.

  2000cites this paper
• Contralateral breast cancer With better survival from breast cancer, more patients are at risk for secondary malignancies, generating a need for more information about contralateral breast cancer [4]. The absolute rate of contralateral cancer among women with a history

  year unknowncites this paper